Vol.62 No.6 November 2014
Clinical practice guidelines for the treatment of pulmonary aspergillosis in non-hematologic disorders
Department of Infectious Disease/Infection Control, Japanese Red Cross Medical Center, 4-1-22 Hiroo, Tokyo, Japan
Abstract
Pulmonary aspergillosis occurs as an opportunistic infection with compromised hosts such as those who have undergone organ transplantation, chemotherapy, and long-term administration of immunosuppressants. Acute invasive pulmonary aspergillosis is a life-threatening illness which typically occurs in neutropenic patients with hematologic malignancy. Chronic pulmonary aspergillosis is furthermore a refractory and progressive disease usually complicated with chronic lung disorders such as the sequelae of tuberculosis, bronchiectasis, emphysema, and so on. Occasionally, fatal respiratory failure and hemoptysis can occur. It has been a long-term challenge for clinicians to manage pulmonary aspergillosis. As several diagnostic methods and anti fungal drugs have been developed in recent years, clinical evidence of diagnosis and therapy for aspergillosis has been accumulated. Thus, the Guidelines for the Diagnosis and Treatment of Deep-Seated Mycosis in Japan were revised in February 2014. These include comprehensive management for diagnosis, therapy, and also infection control. This review article refers to the new guidelines for pulmonary aspergillosis in clinical practice and focuses on pulmonary aspergillosis in non-hematologic disorders, namely those without neutropenic conditions.
Key word
guideline, chronic pulmonary aspergillosis
Received
July 3, 2014
Accepted
August 19, 2014
Jpn. J. Chemother. 62 (6): 657-662, 2014
